The bill amends the New Jersey Menopause Coverage Act to include testosterone therapy as a covered treatment for women experiencing perimenopause and menopause. It mandates that all health insurance carriers, including hospital service corporations, medical service corporations, health maintenance organizations, and various health benefit plans, provide coverage for testosterone therapy on par with other hormonal treatments. Importantly, the bill stipulates that coverage cannot be denied based on the FDA approval status of the therapy for these conditions, thereby ensuring broader access to necessary treatments for women during these transitional phases.

Additionally, the bill requires health benefits plans to provide clear and accessible information regarding covered treatments for perimenopause and menopause. It defines menopause and perimenopause to ensure clarity in understanding these terms within the context of the law. The amendments aim to enhance health benefits for women by ensuring comprehensive care, including hormonal and non-hormonal treatments, behavioral health services, and preventative care. The bill is set to take effect 90 days after enactment, with certain provisions for existing policies to begin on January 1, 2027.

Statutes affected:
Introduced: 17:48-6, 17:48A-7, 17:48E-35.52, 17B:27-46.1, 26:2J-4.53, 17B:27A-7.36, 17B:27A-19.40, 52:14-17.29, 52:14-17.46.6, 30:4D-6